Veracyte Announces First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Veracyte, Inc (VCYT) PT Lowered to $54 at Needham & Company
May 11, 2021 6:34 AM EDTNeedham & Company analyst Stephen Unger lowered the price target on Veracyte, Inc (NASDAQ: VCYT) to $54.00 (from $88.00) while maintaining a Buy rating.
The analyst commented, "VCYT's 1Q21 revenue was in line with its 4/16/21 preannouncement and EPS adjusted for one-time acquisition expenses beat consensus. Organic... More
Veracyte (VCYT) Tops Q1 EPS by 78c, Revenues Beat
May 10, 2021 4:31 PM EDTVeracyte (NASDAQ: VCYT) reported Q1 EPS of $0.66, $0.78 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $36.7 million versus the consensus estimate of $32.67 million.
Total Revenue was $36.7 million, including $3.8 million for urologic cancer testing, an increase of 18%;Gross Margin was 66%;Operating Expenses were $82.1 million. Operating Expenses, Excluding Cost of Revenue, were $69.7 million, including $35.1 million related to... More